Michael Streit | Executive Director, Clinical Development, Oncology R&D
GSK

Michael Streit, Executive Director, Clinical Development, Oncology R&D, GSK

Michael Streit, MD, MBA  is Executive Director and Clinical Development Leader in the Oncology Therapeutic Area of GlaxoSmithKline (GSK) in Collegeville, PA (USA).   
Dr. Streit has a strong and diverse background in biomedical sciences. He received his medical degree and training in Hematology/Oncology at the Free University of Berlin (Germany). Dr. Streit went on to complete a three-year post‐doctoral research fellowship at the Cutaneous Biology Research Center at the Massachusetts General Hospital in Boston (USA) where he also served as research instructor at Harvard Medical School. 
In his first industry assignment Dr. Streit worked as a laboratory‐based Oncology Discovery scientist at Berlex Biosciences on projects in the field of Immune-Oncology. He subsequently received an MBA from Golden Gate University and joined Boehringer‐Ingelheim to conduct clinical development trials for targeted small-molecule inhibitors for the treatment of ilymphoma, pancreatic- and lung cancer. In 2008, Dr. Streit moved to Bristol‐Myers Squibb (BMS) where he led a global development program for a novel anti-angiogenic agent intended for the treatment of hepatocellular cancer. In addition, Dr. Streit developed an interest in translational research and co-chaired the Biomarker Working Group in the Oncology-department at BMS. In 2010, he joined GlaxoSmithKline (GSK) Oncology for the first time to lead the clinical development efforts for the small-molecule inhibitor trametinib. He also played an important role in the development of the small-molecule inhibitor dabrafenib. Dr. Streit was the physician leader of the US and EU filing of trametinib and co-leader of the US-filing of the first combination therapy of the two targeted small molecule inhibitors which were approved as Mekinist and Tafinlar by the FDA in May 2013. 
In June 2013 Dr. Streit joined Janssen, to build early development capabilities in the hematology- and prostate cancer- disease areas. Michael was instrumental in the IND-filing and the initiation of first-in-human studies for multiple programs including listeria-based immunotherapies, T-cell re-direction antibodies, and a novel agonistic anti-CD40 antibody. 
Dr. Streit re-joined GSK in March 2018 and was appointed Medicine Development Leader for the Bintrafusp alfa (formerly known as M7824), a co-development project of Merck KgaA (EMD-Serono) and GSK.

back to speakers

There are two parts to the Festival of Biologics: the five world-class international conferences covering Antibodies, Immunotherapy, BioSimilars, Clinical Trials, and High Potency APIs; and an exhibition featuring the most exciting technology and solutions for pharma and biotech. There is a registration fee to attend the conferences. To visit the exhibition is free.


Conference 29 - 31 October • Exhibition & Seminars 29 - 31 October 

Sign Up for Event Updates